Cargando…

A new promising biological agent for refractory lupus nephritis: Telitacicept

Detalles Bibliográficos
Autores principales:	Liu, Shuangyan, Yu, Xiangyue, Li, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364275/ https://www.ncbi.nlm.nih.gov/pubmed/37492333 http://dx.doi.org/10.12669/pjms.39.4.7542

Ejemplares similares

Efficacy and safety of Telitacicept in patients with IgA nephropathy
por: Liang, Dongrui, et al.
Publicado: (2023)

Telitacicept for autoimmune nephropathy
por: Cai, Jingjing, et al.
Publicado: (2023)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

Secukinumab on Refractory Lupus Nephritis
por: Costa, Rita, et al.
Publicado: (2021)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
por: Jin, Hui-Zhi, et al.
Publicado: (2023)

Role of telitacicept in the treatment of IgA nephropathy
por: Wu, Lijun, et al.
Publicado: (2023)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

Management of refractory lupus nephritis: challenges and solutions
por: Yo, JH, et al.
Publicado: (2019)

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022)

Treatment of refractory lupus nephritis using leflunomide: A prospective study
por: Zhang, Shuo, et al.
Publicado: (2023)

Efficacy and Safety of Biologic Agents for Lupus Nephritis: A Systematic Review and Meta-analysis
por: Chen, Pang, et al.
Publicado: (2023)

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
por: Lv, Jicheng, et al.
Publicado: (2022)

Ætiology of Nephritis
por: Birks, P. H.
Publicado: (1946)

Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue
por: Benjachat, Thitima, et al.
Publicado: (2015)

Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis
por: Lee, Young Ho, et al.
Publicado: (2023)

Low-Dose Interleukin-2 as an Alternative Therapy for Refractory Lupus Nephritis
por: Zhang, Xia, et al.
Publicado: (2021)

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis
por: Huang, Yun-Ju, et al.
Publicado: (2022)

Individualizing Therapy in Lupus Nephritis
por: An, Yu, et al.
Publicado: (2019)

Metabolic Markers and Association of Biological Sex in Lupus Nephritis
por: Wolf, Bethany, et al.
Publicado: (2023)

Good efficacy achieved by telitacicept, corticosteroids and immunosuppressants in the treatment of SLE combined with MOG-AD
por: Tian, Mengxue, et al.
Publicado: (2023)

Fetal and maternal outcome in patients with active lupus nephritis: comparison between new-onset and pre-existing lupus nephritis
por: Lian, Xing-Ji, et al.
Publicado: (2021)

Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities
por: Neves, Ana, et al.
Publicado: (2023)

Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010)

Thyroid Extract in the Treatment of Nephritis
por: Eapen, S. J.
Publicado: (1925)

Thyroid Extract in the Treatment of Nephritis
por: Bouche, B. J.
Publicado: (1925)

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023)

Echinomycin as a promising therapeutic agent against KSHV-related malignancies
por: Chen, Jungang, et al.
Publicado: (2023)

O07 Managing relapsing and refractory lupus nephritis in juvenile systemic lupus erythematosus: a case report
por: Javed, Farhan, et al.
Publicado: (2021)

Old and New Calcineurin Inhibitors in Lupus Nephritis
por: Ponticelli, Claudio, et al.
Publicado: (2021)

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis
por: Huang, Yun-Ju, et al.
Publicado: (2022)

Lupus Nephritis and Dysbiosis
por: Monticolo, Marta, et al.
Publicado: (2023)

The Pathogenesis of Lupus Nephritis
por: Sterner, Rosalie M., et al.
Publicado: (2014)

Pediatric lupus nephritis
por: Pinheiro, Sergio Veloso Brant, et al.
Publicado: (2018)

Hyperhomocysteinemia and Lupus Nephritis
por: Timlin, Homa, et al.
Publicado: (2019)

Management of Lupus Nephritis
por: Tamirou, Farah, et al.
Publicado: (2021)

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Onset of Remission Following COVID-19 Infection in a Patient with Refractory Lupus Nephritis
por: Sathiavageesan, Subrahmanian
Publicado: (2022)

OA19 A case of severe refractory lupus enteritis and nephritis that remitted with Obinutuzumab
por: Chakravorty, Mithun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2idvuhnl2jf7gstd6srk7c9hg2